Most US men skip prostate MRI despite global standard
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Prostate cancer is the most frequently diagnosed cancer in U.S. men, with over 333,000 new cases annually, yet only about 4% become lethal and the 5-year survival rate is 99%.
- MRI scans before biopsy are standard in Europe, Canada, Australia, and the U.K., where they help avoid unnecessary biopsies in 30% to 50% of patients and reduce overdiagnosis of low-grade tumors.
- U.S. guidelines from the National Comprehensive Cancer Network strongly recommend pre-biopsy MRI, but the American Urological Association and ASCO give only a conditional recommendation despite high-level evidence.
- Only about a third of U.S. men received an MRI before biopsy in 2022, leaving the majority to undergo systematic biopsies after elevated PSA tests, increasing risks of complications and overdiagnosis.
- Scott Eggener of UCLA argues many low-grade prostate lesions 'shouldn’t even be called cancer,' reflecting a growing expert consensus that current U.S. diagnosis practices lead to overdiagnosis.
- Mark Emberton of University College London calls the U.S. lag in MRI adoption 'one of the world’s worst global scandals,' criticizing the continued use of less accurate, invasive biopsies.
Why it matters: Hundreds of thousands of U.S. men each year face unnecessary biopsies and treatments due to a slow shift toward MRI-based diagnosis, despite level-one evidence and global adoption—putting patient safety and healthcare efficiency at risk while benefiting providers who rely on biopsy volume for income.
Ask SkimNews
